What is Treos Bio?
Treos Bio is a clinical-stage biopharmaceutical company dedicated to pioneering off-the-shelf peptide active cancer immunotherapies. Their innovative approach targets tumor and patient heterogeneity by utilizing proprietary therapeutic peptides designed to elicit potent cancer-specific immune responses. This method aims to benefit genetically diverse patient populations without the necessity of tumor biopsies. The company's lead candidate, PolyPEPI1018, is focused on colorectal cancer and has demonstrated encouraging results in stimulating robust immunological activity.
How much funding has Treos Bio raised?
Treos Bio has raised a total of $22M across 2 funding rounds:
Private Equity
$8M
Debt
$14M
Private Equity (2017): $8M, investors not publicly disclosed
Debt (2021): $14M led by Future Fund and Luminous Ventures
Key Investors in Treos Bio
Future Fund
Future Fund, established in 2006, is an Australian sovereign wealth fund focused on investing for future generations and easing government financial pressures.
Luminous Ventures
Luminous Ventures is an investment firm that likely focuses on supporting innovative companies, potentially within the technology or life sciences sectors, given its domain.
What's next for Treos Bio?
With a substantial capital infusion, Treos Bio is strategically positioned for accelerated growth and the advancement of its innovative cancer treatment pipeline. The recent major strategic investment signals strong confidence from backers in the company's potential to disrupt the oncology market. This backing will likely fuel further clinical development, expand research initiatives, and support the company's mission to make its peptide-based immunotherapies accessible to a global patient base, potentially marking a new era in personalized cancer care.
See full Treos Bio company page
